{"id":738,"date":"2020-09-18T00:00:00","date_gmt":"2020-09-18T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/09\/18\/details-emerge-on-unexplained-illness-in-astrazeneca-covid-19-vaccine-trial\/"},"modified":"2020-09-21T16:10:07","modified_gmt":"2020-09-21T16:10:07","slug":"details-emerge-on-unexplained-illness-in-astrazeneca-covid-19-vaccine-trial","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/09\/18\/details-emerge-on-unexplained-illness-in-astrazeneca-covid-19-vaccine-trial\/","title":{"rendered":"Details Emerge on Unexplained Illness in AstraZeneca COVID-19 Vaccine Trial"},"content":{"rendered":"<h3>Healthy 37-year-old woman &#8216;experienced confirmed transverse myelitis&#8217; after receiving second dose of vaccine<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>FRIDAY, Sept. 18, 2020 (HealthDay News) &#8212; New details surfaced on Thursday on an unexplained neurological condition that struck a volunteer who was participating in AstraZeneca&#8217;s COVID-19 vaccine trial.<\/p>\n<p>In an internal safety report obtained by <i>CNN<\/i>, company officials describe how a healthy 37-year-old woman &#8220;experienced confirmed transverse myelitis&#8221; after receiving her second dose of the vaccine. She was hospitalized on Sept. 5. The report describes how the patient had the first dose of the COVID-19 vaccine in early June and was fine. She received her second dose in late August. While out running on Sept. 2, she &#8220;had a trip (not fall) with a jolt.&#8221; The report noted that she did not have any obvious injury to her spine when examined, according to <i>CNN<\/i>. The next day, the report said, she had difficulty walking, pain and weakness in her arms, pain and reduced sensation in her torso, a headache, and reduced ability to use her hands.<\/p>\n<p>The report mentions twice that the woman was diagnosed with &#8220;confirmed&#8221; transverse myelitis. No other similar cases have been diagnosed among study volunteers, according to the report. The woman&#8217;s neurologist also noted that the woman has started to feel better. The report, dated Sept. 10, was sent out on Sept. 11 to doctors who are running the study&#8217;s clinical trial sites, <i>CNN<\/i> reported. Last week, AstraZeneca announced the volunteer&#8217;s &#8220;unexplained illness&#8221; and said it was pausing the trial worldwide. The British and Brazilian arms of the trial have since resumed; the U.S. arm has not.<\/p>\n<p>Anthony Fauci, M.D., director of the U.S. National Institute of Allergy and Infectious Diseases, told <i>CNN<\/i> this week that it is &#8220;just a matter of time&#8221; before the trial resumes in the United States.&#8221; He added that he considered the participant&#8217;s illness a &#8220;one-off&#8221; at this point and that &#8220;it would be unusual to completely stop a trial on the basis of one single adverse event.&#8221; He said doctors leading the trial&#8217;s U.S. sites will be told to look out for similar symptoms. &#8220;You have to be extra special careful and watch out to see if it happens again, and then if it does, it becomes an entirely different situation,&#8221; he told <i>CNN<\/i>.<\/p>\n<p><a href=\"https:\/\/www.cnn.com\/2020\/09\/17\/health\/astrazeneca-vaccine-trial-document\/index.html\" target=\"_new\" rel=\"noopener noreferrer\"><i>CNN<\/i> Article<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Healthy 37-year-old woman &#8216;experienced confirmed transverse myelitis&#8217; after receiving second dose of vaccine<\/p>\n","protected":false},"author":4,"featured_media":763,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/738"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=738"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/738\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/763"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=738"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}